Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 11/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6597981 | 1.00 | SLC18A3 (0.72) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL6597979 | 1.00 | SLC18A3 (0.72) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL10960265 | 1.00 | SLC18A3 (0.72) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL6597975 | 1.00 | SLC18A3 (0.72) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL6596292 | 1.00 | SLC18A3 (0.72) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL6593610 | 1.00 | SLC18A3 (0.72) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL8989808 | 1.00 | SLC18A3 (0.72) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL11346322 | 1.00 | SLC18A3 (0.72) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL11346290 | 1.00 | SLC18A3 (0.72) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL10960261 | 1.00 | SLC18A3 (0.72) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179233-A1 | PROCESS AND CATALYSTS FOR HYDROGEN MEDIATED ANIONIC COPOLYMERIZATION OF CONJUGATED DIENES AND LIQUID COPOLYMERS THEREOF | ALBEMARLE CORPORATION (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4486808-A2 | PROCESS AND CATALYSTS FOR HYDROGEN MEDIATED ANIONIC COPOLYMERIZATION OF CONJUGATED DIENES AND LIQUID COPOLYMERS THEREOF | ALBEMARLE CORPORATION (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240034825-A1 | PROCESS AND CATALYSTS FOR HYDROGEN MEDIATED ANIONIC POLYMERIZATION OF CONJUGATED DIENES AND LIQUID POLYMERS THEREOF | ALBEMARLE CORPORATION | 2024-02-01 | — | — | US | disclosed |
| WO-2023168218-A2 | PROCESS AND CATALYSTS FOR HYDROGEN MEDIATED ANIONIC COPOLYMERIZATION OF CONJUGATED DIENES AND LIQUID COPOLYMERS THEREOF | ALBEMARLE CORPORATION (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-4208485-A1 | PROCESS AND CATALYSTS FOR HYDROGEN MEDIATED ANIONIC POLYMERIZATION OF CONJUGATED DIENES AND LIQUID POLYMERS THEREOF | ALBEMARLE CORPORATION (US) | 2023-07-12 | — | — | EP | disclosed |
| US-8008342-B2 | Ion channel modulating compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2011-08-30 | — | — | US | disclosed |
| US-20110207730-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2011-08-25 | — | — | US | disclosed |
| US-7875611-B2 | (+)-trans-[2-(4-morpholinyl)-1-[2-(2-naphthoxy)ethoxy)]; (1R,2R)/(1S,2S)-2-[1,4-dioxa-7-azaspiro[4.4]non-7-yl]-1-(1-naphthenethoxy)cyclohexanecyclohexane; treatment of arrhythmia and the production of analgesia and local anesthesia | CARDIOME PHARMA CORP. (CA) | 2011-01-25 | — | — | US | disclosed |
| US-20100056603-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2010-03-04 | — | — | US | disclosed |
| US-20100029639-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2010-02-04 | — | — | US | disclosed |
| US-6060488-A | ANTICARCINOGENIC AGENTS; POSTMENOPAUSAL CANCER OF BREASTS, UTERUS, CERVIX | ELI LILLY AND COMPANY (US) | 2000-05-09 | — | — | US | disclosed |
| US-6025382-A | Antithrombotic diamines | ELI LILLY AND COMPANY (US) | 2000-02-15 | — | — | US | disclosed |
| WO-1999015521-A1 | BENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 1999-04-01 | — | — | WO | disclosed |
| EP-0905132-A1 | Benzothiophenes | ELI LILLY AND COMPANY (US) | 1999-03-31 | — | — | EP | disclosed |
| EP-0863755-A4 | ANTITHROMBOTIC DIAMINES | LILLY CO ELI (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0863755-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997025033-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1997-07-17 | — | — | WO | disclosed |
| EP-0072620-B1 | 3-METHYLFLAVONE-8-CARBOXYLIC ACID ESTERS | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1985-12-04 | — | — | EP | disclosed |
| US-4550115-A | ANTISPASMODIC, CALCIUM BLOCKER, ANESTHETIC, AND ANTINFLAMMATORY AG | RECORDATI S.A., CHEMICAL & PHARMACEUTICAL COMPANY (CH) | 1985-10-29 | — | — | US | disclosed |
| EP-0072620-A1 | 3-Methylflavone-8-carboxylic acid esters | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1983-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207730-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | SLC18A3 208/4885CYP2D6 1182/4885TSHR 2898/4885 |
| US-20100056603-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | SLC18A3 208/4885CYP2D6 1182/4885TSHR 2898/4885 |
| US-20100029639-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | SLC18A3 208/4885CYP2D6 1182/4885TSHR 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.